Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy

MLA

Stakišaitis, Donatas, et al. “Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy.” Therapeutic Innovation and Regulatory Science, vol. 53, no. 4, July 2019, pp. 549–53. EBSCOhost, https://doi.org/10.1177/2168479018795857.

APA

Stakišaitis, D., Zamaryte-Sakaviciene, K., Lesauskaite, V., & Jankunas, R. J. (2019). Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy. Therapeutic Innovation and Regulatory Science, 53(4), 549–553. https://doi.org/10.1177/2168479018795857

Chicago

Stakišaitis, Donatas, Kristina Zamaryte-Sakaviciene, Vita Lesauskaite, and Rimas Jonas Jankunas. 2019. “Off-Label Use of Antipsychotic Agents in Dementia: Evidence for the Revision of the Reimbursement Policy.” Therapeutic Innovation and Regulatory Science 53 (4): 549–53. doi:10.1177/2168479018795857.